B. Metzler seel. Sohn & Co. AG Lowers Stake in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI)

B. Metzler seel. Sohn & Co. AG lessened its holdings in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) by 45.0% in the 4th quarter, Holdings Channel.com reports. The firm owned 18,305 shares of the biopharmaceutical company’s stock after selling 14,986 shares during the quarter. B. Metzler seel. Sohn & Co. AG’s holdings in Intra-Cellular Therapies were worth $1,529,000 at the end of the most recent reporting period.

A number of other large investors also recently bought and sold shares of the business. Norges Bank purchased a new stake in shares of Intra-Cellular Therapies in the fourth quarter valued at approximately $268,347,000. Raymond James Financial Inc. purchased a new stake in Intra-Cellular Therapies in the 4th quarter worth $76,451,000. TimesSquare Capital Management LLC raised its position in Intra-Cellular Therapies by 91.8% during the fourth quarter. TimesSquare Capital Management LLC now owns 840,269 shares of the biopharmaceutical company’s stock worth $70,179,000 after acquiring an additional 402,186 shares during the period. Franklin Resources Inc. lifted its holdings in Intra-Cellular Therapies by 9.7% during the third quarter. Franklin Resources Inc. now owns 1,753,286 shares of the biopharmaceutical company’s stock valued at $129,463,000 after purchasing an additional 155,655 shares in the last quarter. Finally, Vanguard Group Inc. grew its position in shares of Intra-Cellular Therapies by 1.0% in the fourth quarter. Vanguard Group Inc. now owns 9,721,360 shares of the biopharmaceutical company’s stock valued at $811,928,000 after purchasing an additional 93,107 shares during the period. Institutional investors and hedge funds own 92.33% of the company’s stock.

Analyst Ratings Changes

A number of research analysts recently weighed in on the stock. Royal Bank of Canada reaffirmed a “sector perform” rating and issued a $132.00 price target (up from $108.00) on shares of Intra-Cellular Therapies in a research note on Wednesday, January 22nd. Cantor Fitzgerald reiterated a “neutral” rating and set a $132.00 price target on shares of Intra-Cellular Therapies in a research report on Wednesday. Needham & Company LLC restated a “hold” rating on shares of Intra-Cellular Therapies in a report on Friday, February 21st. Leerink Partnrs lowered shares of Intra-Cellular Therapies from a “strong-buy” rating to a “hold” rating in a report on Monday, January 13th. Finally, StockNews.com began coverage on shares of Intra-Cellular Therapies in a research note on Friday, March 28th. They issued a “hold” rating on the stock. Eleven investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. According to MarketBeat.com, Intra-Cellular Therapies has an average rating of “Hold” and a consensus price target of $106.23.

Intra-Cellular Therapies Stock Down 0.0 %

NASDAQ:ITCI opened at $131.91 on Thursday. The company has a market capitalization of $14.05 billion, a P/E ratio of -151.62 and a beta of 0.69. Intra-Cellular Therapies, Inc. has a 52 week low of $64.09 and a 52 week high of $131.98. The stock’s fifty day moving average is $129.43 and its two-hundred day moving average is $100.82.

Intra-Cellular Therapies (NASDAQ:ITCI) last announced its quarterly earnings results on Friday, February 21st. The biopharmaceutical company reported ($0.16) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.08) by ($0.08). The company had revenue of $199.22 million for the quarter, compared to analyst estimates of $205.08 million. Intra-Cellular Therapies had a negative net margin of 14.07% and a negative return on equity of 9.93%. Sell-side analysts anticipate that Intra-Cellular Therapies, Inc. will post -0.64 earnings per share for the current fiscal year.

Intra-Cellular Therapies Profile

Intra-Cellular Therapies, Inc, a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States.